Gemcitabine hydrochloride is under clinical development by RenovoRx and currently in Phase III for Pancreatic Cancer. According to GlobalData, Phase III drugs for Pancreatic Cancer have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Gemcitabine hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gemcitabine hydrochloride overview
RenovoGem is under development for the treatment of locally advanced pancreatic cancer (LAPC), bile duct cancer (extrahepatic cholangiocarcinoma-eCCA), lung cancer, uterine tumors, and glioblastoma. It is administered through intraarterial route and acts by targeting ribonucleotide reductase. RenovoGem is a combination of gemcitabine and the patented delivery system, RenovoCath. The drug candidate is being developed based on RenovoTAMP-Trans-arterial micro-perfusion therapy platform.
RenovoRx is a medical device company. The company develops solutions for targeted delivery of diagnostic, therapeutic agents and chemotherapeutic drugs targeting peripheral vascular system. It’s proprietary Trans-Arterial Micro-Perfusion (TAMP), technology platform provides chemotherapy for the treatment of solid tumors in the peripheral system. RenovoRx lead product RenovoCath, a medical device system with dual-balloon infusion catheter that delivers intra-arterial chemotherapy directly to the tumor. It also investigating TIGeR-PaC, a systemic chemotherapy for pancreatic cancer. RenovoRx is headquartered in Los Altos, California, the US.
For a complete picture of Gemcitabine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.